| Autor: |
K D, Wilner, S B, Demattos, R J, Anziano, G, Apseloff, N, Gerber |
| Rok vydání: |
2000 |
| Předmět: |
|
| Zdroj: |
British journal of clinical pharmacology. 49 |
| ISSN: |
0306-5251 |
| Popis: |
To determine whether ziprasidone alters the metabolizing activity of the 2D6 isoenzyme of cytochrome P450 (CYP2D6).Twenty-four healthy young subjects aged 18-45 years were screened for CYP2D6 metabolizing activity and shown to be extensive metabolizers of dextromethorphan. These subjects were then randomized to receive a single dose of ziprasidone 80 mg, paroxetine 20 mg or placebo, 2 h before receiving a dose of dextromethorphan. Urine samples for the determination of dextromethorphan concentrations were collected over the 8 h period following dextromethorphan dosing, and used for the determination of dextromethorphan/dextrorphan ratios. Blood samples were collected immediately before and up to 10 h after the administration of ziprasidone or paroxetine, and used to derive pharmacokinetic parameters of ziprasidone and paroxetine.There were no statistically significant changes in the urinary dextromethorphan/dextrorphan ratio in the ziprasidone group or the placebo group. By contrast, there was a 10-fold increase in the urinary dextromethorphan/dextrorphan ratio in the paroxetine group and this differed significantly from those in the ziprasidone and placebo groups (P = 0.0001).The findings of this study suggest that ziprasidone does not inhibit the clearance of drugs metabolized by CYP2D6. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text